|
13 Jan 2020 |
Moderna Builds on Clinical Validation of Systemic Delivery with Two Additional Development Candidates in New Autoimmune Therapeutic Area
|
|
13 Jan 2020 |
Adaptimmune Announces that SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor Indications
|
|
12 Jan 2020 |
LogicBio Therapeutics Announces Collaboration with Takeda to Develop New Genome Editing Candidate LB-301 for the Treatment of Crigler-Najjar Syndrome
|
|
12 Jan 2020 |
LogicBio Therapeutics Announces Submission of Investigational New Drug Application (IND) for LB-001 for Methylmalonic Acidemia (MMA) and Highlights Key Corporate Milestones
|
|
12 Jan 2020 |
Announcement of iPSC Derived Gene-modified NK Cell Development Targeting Solid Tumors
|
|
12 Jan 2020 |
PACT Pharma Raises $75M in Oversubscribed Series C Financing to Develop Fully Personalized NeoTCR-T Cell Therapies for Patients with Cancer
|
|
12 Jan 2020 |
Moderna Announces Additional Positive Phase 1 Data from Cytomegalovirus (CMV) Vaccine (mRNA-1647) and First Participant Dosed in Phase 2 Study
|
|
12 Jan 2020 |
Generation Bio Announces $110 Million Series C Financing to Advance Lead Programs for Hemophilia A and PKU
|
|
12 Jan 2020 |
Indapta Therapeutics and Lonza Announce Strategic Partnership to Advance a Next-generation, Off-the-shelf, Allogeneic Immuno-oncology Therapy
|
|
12 Jan 2020 |
Alnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 (PH1)
|
|
12 Jan 2020 |
Akcea and Ionis Announce Initiation of CARDIO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with TTR-mediated Amyloid Cardiomyopathy
|
|
09 Jan 2020 |
Clinical Trial of Autologous Hematopoietic Stem Cell Transplantation versus Best Available Therapy for Multiple Sclerosis (BEAT-MS) Begins Enrollment
|
|
09 Jan 2020 |
Gracell Initiates Investigational Study of the Technological Breakthrough TruUCAR™ Therapy for Relapsed or Refractory T-cell Malignancies
|
|
09 Jan 2020 |
Locus Biosciences initiates world's first controlled clinical trial for a CRISPR enhanced bacteriophage therapy
|
|
09 Jan 2020 |
Finch Therapeutics Completes Enrollment in Potentially Pivotal Trial of CP101, an Investigational Oral Full-Spectrum Microbiota® Therapy for the Prevention of Recurrent C. difficile Infection
|
|
08 Jan 2020 |
Promethera announces Initiation of Phase 2b DHELIVER Study of HepaStem™ in patients with Acute-on-Chronic Liver Failure (ACLF)
|
|
06 Jan 2020 |
Clinical Update - 4D Announce New Study of MRx0518 in Pancreatic Cancer
|
|
03 Jan 2020 |
BioNTech Announces Publication of Preclinical Data for First-in-Kind CAR-T Cell Therapy Approach Targeting Solid Tumors in Science
|
|
02 Jan 2020 |
Gamida Cell Announces Completion of Patient Enrollment in Ongoing Phase 3 Clinical Study of Omidubicel
|
|
30 Dec 2019 |
Wave Life Sciences Announces Topline Data and Addition of Higher Dose Cohort in Ongoing Phase 1b/2a PRECISION-HD2 Trial in Huntington’s Disease
|
|
26 Dec 2019 |
Prevail Therapeutics Announces IND Active for PR001 for Treatment of Neuronopathic Gaucher Disease
|
|
23 Dec 2019 |
BioMarin Submits Biologics License Application to U.S. Food and Drug Administration for Valoctocogene Roxaparvovec to Treat Hemophilia A
|
|
23 Dec 2019 |
Urovant Sciences Initiates Patient Enrollment in Phase 2a Study of URO-902
|
|
21 Dec 2019 |
Longeveron LLC Announces Completion of Enrollment in Phase 1 Clinical Trial of Longeveron Allogeneic Mesenchymal Stem Cells (LMSCs) in Alzheimer's Disease
|
|
21 Dec 2019 |
Arrowhead Pharmaceuticals Doses First Patient in AROAAT2002 Open Label Phase 2 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
|
